New drug plus standard chemo for spread colorectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new drug called SAR445877 combined with two standard chemotherapies (FOLFOX and bevacizumab) as an initial treatment for people whose colorectal cancer has spread and is microsatellite stable (MSS). It aims to see if adding this drug works better than standard therapy alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with stage 4 colorectal cancer that is microsatellite stable (MSS).
- You have not had any treatment for cancer that has spread, except possibly FOLFOX after surgery but at least 6 months ago.
- You have at least one tumor that can be measured with a scan.
- You are physically able to do daily activities (ECOG 0 or 1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug combined with standard chemotherapy and another medication for people with advanced colorectal cancer that has a specific genetic change (RAS mutation). It aims to see if the combination can help control the cancer better.
This trial tests a combination of drugs for people with advanced colorectal cancer that has worsened after first treatment. It aims to see if this new mix can help control the cancer better.
This trial tests a new drug combination for advanced colorectal cancer that has not gotten better with standard chemotherapy. It is for people whose tumors have normal RAS and BRAF genes, and it adds a new type of medicine (HCB101) to a common chemotherapy plus targeted therapy regimen.
This trial tests a new drug combination for people with colorectal cancer that has spread and cannot be removed by surgery. It compares the new drug plus standard chemotherapy against a placebo plus the same chemotherapy, to see if it helps shrink tumors and slow the disease.
This trial tests whether adding an experimental drug (INCA33890) to standard chemotherapy and bevacizumab helps people with a certain type of advanced colorectal cancer. It is for those whose cancer has spread and has not been treated yet with systemic therapy.
This trial tests a new combination of drugs (Retlirafusp Alfa, Bevacizumab, and chemotherapy) with or without a short course of radiation for people with colorectal cancer that has spread only to the liver and who have not had any prior treatment. The goal is to see if this approach is safe and effective.
Hear when a new Phase 1 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.